Evion Group Seeks ASX Quotation for 11.9 Million Shares Linked to Carp Fluorspar Acquisition

Evion Group’s Market Position and Business Overview

Evion Group NL is an ASX-listed company focused on acquiring and developing mineral assets. The company pursues strategic transactions aimed at enhancing shareholder value through the acquisition of mineral-rich properties and advancing exploration and development initiatives. Currently, Evion is actively expanding its portfolio with a focus on fluorspar resources via its proposed acquisition of Carp Fluorspar Pty Ltd. The company’s capital structure includes multiple share classes and performance rights, reflecting its active acquisition strategy and management incentive plans.

The acquisition of Carp Fluorspar marks a key step in Evion’s strategy to build a diversified mineral asset base. Utilizing equity as acquisition consideration is a common approach among junior mineral explorers and developers to conserve cash while securing valuable assets. Following this application, Evion’s issued capital will exceed 746 million quoted shares, underscoring the capital-intensive nature of mineral acquisitions and development.

Strategic Importance of the Carp Fluorspar Acquisition

Evion Group’s acquisition of a 100% stake in Carp Fluorspar Pty Ltd represents a strategic expansion of its mineral holdings. Under the Option Agreement, shares are being issued as partial payment for the asset. The current quotation application covers 11.9 million shares issued as partial consideration, highlighting a staged acquisition process. Fluorspar is an industrial mineral critical to sectors such as metallurgy, chemical manufacturing, and uranium enrichment, making it a strategically valuable commodity. Full ownership indicates Evion’s intent to maintain complete operational control post-acquisition.

The staged consideration, with 11.9 million shares issued now and additional deferred shares to be issued later, aligns with milestone-based payment structures. This mechanism allows risk management and value verification for both parties. The 18 million shares allocated as corporate advisory fees, yet to be issued, reflect the transaction’s complexity and the involvement of specialist advisors. Shareholders were informed of these terms in the Notice of Meeting lodged on 9 June 2026.

Details of Share Issuance and Consideration Structure

The application pertains to the quotation of 11,939,458 fully paid ordinary shares issued on 21 July 2026. These shares were issued without cash payment, serving as partial consideration under the Option Agreement for Carp Fluorspar Pty Ltd. The company did not specify a per-share value, indicating the consideration was negotiated directly with the vendor rather than set by market pricing. Equity-based consideration is typical in mineral asset acquisitions where vendors seek upside potential.

The transaction involves multiple share issuance events. Beyond these 11.9 million shares, Evion has indicated further issuances remain, including 18 million shares for corporate advisory fees (on terms consistent with the 12 May 2026 announcement) and deferred consideration shares. This phased issuance strategy enables Evion to manage its share register and align issuances with acquisition milestones. The absence of a distribution schedule in this application suggests shares were issued to specific counterparties rather than through a broad placement.

Impact on Evion’s Capital Structure and Share Register

Following this quotation, Evion’s total quoted ordinary shares will increase to 746,096,954, marking a significant expansion of its share register. The company’s capital structure includes various share classes, options, and performance rights. Notably, there are 60.8 million options expiring 27 September 2026 with a $0.03 strike price, reflecting prior capital raises or employee incentives. Additionally, performance rights include 13.4 million expiring 22 November 2027, 2 million expiring 30 June 2027, and 6 million from the 2023 series, indicating potential future dilution.

This growth in quoted shares illustrates the capital demands of mineral acquisition and development. Investors should consider potential dilution from outstanding options and performance rights alongside the expanding share base. The lack of a distribution schedule indicates shares were issued as consideration to specific parties rather than via public placement. Further issuances, including the 18 million corporate advisory fee shares and deferred consideration shares, will likely increase the share register before acquisition completion.

Outstanding Share Issuances and Completion Timeline

Evion confirmed that additional share issuances remain to complete the Carp Fluorspar acquisition. The most significant is the 18 million shares for corporate advisory fees, to be issued on terms consistent with the 12 May 2026 announcement. This equity-based fee arrangement highlights the transaction’s complexity and the role of specialist advisors. Additional deferred consideration shares are also pending, though details on quantity, timing, or conditions were not disclosed. Investors should monitor future announcements for updates on these issuances and related milestones.

The staged payment structure indicates the acquisition is progressing through multiple milestones rather than a single transaction. This provides defined triggers for share issuance and value realization. The Notice of Meeting dated 9 June 2026 provided shareholders with detailed transaction disclosures, including rationale for equity consideration and expected completion timelines. Investors seeking further information should consult that notice and subsequent market updates.

Unquoted Securities and Potential Dilution Risks

Evion holds substantial unquoted securities that may convert or vest, posing additional dilution risks. The most immediate is 60.8 million options expiring 27 September 2026 with a $0.03 exercise price, which may be exercised if in-the-money. Medium-term dilution risks include 19.75 million options expiring 22 November 2027 at $0.05 strike and 8 million options expiring the same date at $0.04 strike.

Performance rights also contribute to potential dilution. The company has issued 13.4 million rights expiring 22 November 2027, 2 million expiring 30 June 2027, and 6 million from the 2023 series. Vesting conditions were not disclosed but typically depend on performance or time-based criteria. Additionally, 4,392,186 partly paid ordinary shares exist, potentially requiring further capital calls to become fully paid. Collectively, these unquoted securities could add over 100 million shares to the register, materially diluting existing shareholders.

Context from May 2026 Announcement

The current quotation application references an Appendix 3B lodged on 12 May 2026 titled "Update - Proposed issue of securities - EVG," providing advance market disclosure of the securities to be issued. This transparency allows investors to understand the transaction’s commercial rationale before shares are quoted. The corporate advisory fee shares are issued on terms consistent with this May announcement. The use of Appendix 3B rather than Appendix 3Y confirms these are new issuances rather than amendments to existing securities.

The timeline from May announcement to July quotation aligns with standard regulatory processing and shareholder approval procedures. The company finalized acquisition terms, obtained shareholder approval at the June 2026 meeting, and satisfied conditions precedent before issuing shares. The 9 June 2026 Notice of Meeting enabled shareholders to review transaction details and vote accordingly.

Regulatory and Market Impact of the Quotation

The quotation of 11.9 million shares formally lists these securities on the ASX, enabling trading by investors. This process complies with ASX Listing Rule requirements, confirming the shares meet listing standards and disclosure obligations. Issuing shares as acquisition consideration rather than via placement is common when shares are granted to counterparties like vendors or advisors. The application confirms Evion’s total quoted capital will reach 746,096,954 shares, important information for shareholders assessing dilution.

From a liquidity standpoint, these shares will be tradable on the ASX, though trading volumes and prices will depend on market demand and conditions for junior mineral explorers. No specific share price or expected impact on share price was disclosed. Since the shares were issued for non-cash consideration, no direct cash inflow results from the quotation. However, the increased floating supply may affect price discovery and liquidity for existing and prospective investors.

Key Dates and Shareholder Approval Milestones

Evion has progressed through key milestones in the Carp Fluorspar acquisition. The initial proposed share issuance was announced on 12 May 2026 via Appendix 3B. Shareholders received a Notice of Meeting on 9 June 2026 to approve the acquisition and related share issuances. The current quotation application dated 21 July 2026 represents the final regulatory step enabling trading of the issued shares. This timeline reflects a structured approach encompassing market disclosure, shareholder approval, and regulatory compliance.

Looking ahead, investors should watch for the 27 September 2026 expiry of 60.8 million options, which could trigger further share issuances. The June 2026 Notice of Meeting may provide additional timelines for deferred consideration issuances. Completion of the 18 million corporate advisory fee shares and remaining deferred consideration shares will mark further acquisition milestones. Operational updates on Carp Fluorspar post-acquisition could also influence Evion’s revenue and strategic focus.